• NeuralCloud Solutions, AI/ML Innovations' wholly owned subsidiary, signed a nonbinding agreement with MyCor360+ to explore licensing its MaxYield ECG signal-processing technology.
• The proposed integration targets a cellular-enabled cardiac monitoring device designed for up to 14 days of recording.
• Commercialization requires a definitive agreement, successful technical integration and FDA clearances; neither MaxYield nor the device has clearance for the proposed application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AI/ML Innovations Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.